long-term benefit from 1l maintenance parp inhibitors in ovarian cancer
Published 1 year ago • 51 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:08
should 1l maintenance with parp inhibitors be given to all patients with ovarian cancer?
-
3:45
parp inhibitors for ovarian cancer
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
1:57
7-year os from solo1: sustained benefit with maintenance olaparib
-
59:02
parp inhibitors as first-line maintenance therapy in ovarian cancer
-
1:13
final os results from paola-1 evaluating 1l maintenance olaparib plus bevacizumab
-
35:35
maximizing the potential of parp inhibitors as first-line maintenance therapy in ovarian cancer
-
2:58
standard of care updates in ovarian cancer: parp inhibitors
-
1:53
parp inhibitors: game-changers for ovarian cancer patients?
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
6:52
case 3: benefit of parp inhibitor maintenance in ovarian cancer
-
1:10:07
optimizing the use of parp inhibitors in ovarian cancer
-
58:44
what’s new with parp inhibitors and ovarian cancer?
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
3:37
selecting patients to be treated with maintenance olaparib in the paola-1 trial
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
24:56
gynecologic cancer education: parp inhibitor therapy